The United Kingdom and the United States have reached a important trade agreement that will maintain no duties on British drug shipments entering the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to raise spending on pharmaceuticals through the public health system. This move ensures that duties on these crucial products will be held at zero for a period of 36 months.
This development follows recent threats to dramatically increase tariffs on patented drug products, with increases mentioned reaching double the cost.
"This arrangement with the Britain reinforces the worldwide climate for cutting-edge drugs and brings much-needed equity to American-British drug exports," a statement noted.
Trade Significance
Drugs represent one of the UK's largest goods shipped to the America, which is easily the largest destination for major UK drugmakers.
Trade data show that in the year leading up to the third quarter, the UK shipped drugs worth over eleven billion pounds to the US. This figure made up a significant portion of British export trade in that period.
"This agreement secures jobs, boosts capital expenditure and paves the way for the UK to become a global hub for life sciences," the Business and Trade Secretary remarked.
Detailed UK Commitments
The deal involves several key changes from the British government:
- Revised Affordability Limit: The UK will raise the affordability limit at which it considers new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to increase total NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Refund Ceiling: The amount pharmaceutical firms must refund to the NHS to control costs will be capped at 15%. Previously, refunds topped 20%.
Recent Tensions
The pact follows a ongoing dispute between the sector and the ministers over spending levels and approval rates.
These tensions were exacerbated by claims that American patients were paying significantly more for the identical medicines than people in the other developed nations.
Over the last 18 months, several significant pharmaceutical investments in the UK have been halted or cancelled, while substantial investments have been pledged toward American operations.
The Science Minister stated that the NHS needed to invest a greater share on treatments, noting that its expenditure on drugs had shrunk as a share of its overall budget over the previous ten-year period.
